Health technology assessment (HTA) is the systematic evaluation of a health technology's (drug, device, procedure, or program) clinical effectiveness, cost-effectiveness, and broader impact to inform coverage, reimbursement, and pricing decisions. HTA bodies like the UK's NICE, Australia's PBAC, and Canada's CADTH review manufacturer-submitted evidence and independent analyses to determine whether a technology provides sufficient value for money to warrant public funding. The HTA process integrates clinical evidence (does it work?), economic evaluation (is the ICER acceptable?), budget impact analysis (can we afford it?), and broader considerations (equity, innovation incentives, patient preferences). HTA institutionalizes the economic principle that healthcare resources are scarce and allocation decisions should be informed by systematic evidence assessment rather than political lobbying or marketing.
The development of a new drug or medical device involves billions of dollars in R&D, clinical trials, and regulatory approval. But regulatory approval (FDA, EMA) certifies only that the technology is safe and efficacious — it does not determine whether it is worth paying for with public money. Health technology assessment fills this gap by systematically evaluating whether the health gains justify the cost, given the reality of finite healthcare budgets.
The HTA process typically involves four components. Clinical effectiveness assessment reviews the evidence that the technology works — what is the magnitude of benefit, how certain is the evidence, and how does it compare to current standard of care? Economic evaluation estimates the ICER, usually in cost per QALY, using a decision-analytic model that projects costs and outcomes over the relevant time horizon (often lifetime). Budget impact analysis estimates the total cost to the healthcare system of adopting the technology, given the size of the eligible population and expected uptake. Broader considerations include equity (does the technology serve disadvantaged groups?), innovation (does rejecting it discourage future R&D?), and patient preferences.
NICE (the UK's National Institute for Health and Care Excellence) is the most influential HTA body globally. Its standard cost-effectiveness threshold of £20,000-30,000 per QALY means that technologies with ICERs below this range are normally recommended, those above are normally rejected, and those near the boundary require additional justification. NICE publishes its methods, evidence reviews, and decisions transparently, creating a body of precedent that influences HTA practice worldwide.
HTA is fundamentally about making explicit the tradeoffs that every healthcare system makes implicitly. Without HTA, coverage decisions are driven by political pressure, pharmaceutical marketing, or historical precedent — none of which systematically considers value for money. With HTA, a new drug that costs $300,000 per patient for 2 months of additional survival is evaluated against the same framework as a preventive screening program that costs $50 per person. This does not eliminate difficult choices — it ensures they are informed by evidence and made transparently.
No topics depend on this one yet.